Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

VA Health Systems Research

Go to the VA ORD website
Go to the QUERI website

HSR&D Citation Abstract

Search | Search by Center | Search by Source | Keywords in Title

Comparative cost savings of biosimilar and dose rounding utilization in oncology care.

Abdelmeseh V, Brown BR, Huynh JP, Zullo AR. Comparative cost savings of biosimilar and dose rounding utilization in oncology care. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2023 Sep 1; 29(6):1437-1442.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.
   Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions


INTRODUCTION: The exponential rise in cancer costs has led many centers to utilize dose rounding to the nearest vial size when the difference in dose is = 10% to decrease costs. The recent approval of several biosimilar products has presented another opportunity to mitigate the rising costs of oncology care. Scarce information exists about the expected cost savings of combining dose rounding strategies (DRS) with biosimilar use (BU). We therefore assessed the cost savings of combining DRS and BU. METHODS: Electronic health record data for two health systems in Rhode Island were used to identify patients who received = 1 of trastuzumab, trastuzumab-anns, bevacizumab, or bevacizumab-awwb from October 1, 2015 to September 1, 2020. Costs were estimated using Medicare drug pricing. Multivariable generalized estimating equations adjusting for age, gender, presence of metastases, dosing weight, and dose administered were used to compare costs per dose between the four exposure groups: DRS?+?BU, DRS only, BU only, and neither DRS or BU. RESULTS: A total of 1156 patients were administered 15,145 doses of drug. After covariate adjustment, average savings per dose was greatest in the DRS?+?BU group (vs. the neither DRS nor BU group); $331 for trastuzumab and $497 for bevacizumab. CONCLUSIONS: Combining dose rounding with biosimilar substitution for trastuzumab and bevacizumab resulted in significant cost savings per dose and should be implemented by healthcare systems.

Questions about the HSR website? Email the Web Team

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.